# An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe

> **NCT05559606** · — · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 1839 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05559606
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-07
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 1839 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559606, "An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05559606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*